Since the expression of these ER receptor subtypes is lost in CRC tumor progression, it remains to be determined if estrogen and GPER can modulate sexual dimorphism in CRC cell survival through metabolic reprogramming under hypoxic conditions. The gene discussed is GPER1; the disease is neoplasm.